Ventricular Assist Devices Market - By Product, By Application, By Patient, By Flow, By Design, By End Use - Global Forecast, 2025 - 2034

Ventricular Assist Devices Market Size

The global ventricular assist devices market was valued at USD 2.5 billion in 2024. The market is expected to grow from USD 2.7 billion in 2025 to USD 5.7 billion in 2034, at a CAGR of 8.4% during the forecast period, according to the latest report published by Global Market Insights Inc. The high market growth is attributed to the increase in the number of heart failures and cardiovascular diseases, rising awareness regarding heart failure treatment, and a shortage of heart donors, among other factors.

Ventricular assist devices (VADs) provide therapeutic aid for patients with severe heart failure by mechanically augmenting cardiac output, either on a temporary or permanent basis. Abbott, Johnson & Johnson, Berlin Heart, and Jarvik Heart are major players in the VAD market, among others. These manufacturers produce a range of implantable VADs, percutaneous micro-axial pumps, and paracorporeal external systems, for both acute care facilities and long-term outpatient therapy.
 

The market has increased from USD 1.7 billion in 2021 and reached USD 2.2 billion in 2023, with a historic growth rate of 13.5%. This was mainly propelled by increased prevalence of advanced heart failure, device design-related technological advancements, and broadening applications in various healthcare settings.
 

According to the National Institutes of Health, as of 2021, heart failure had reached an estimated 55.5 million individuals globally, which is close to doubling from the 1990 number of 25.4 million cases. This increase primarily results from population aging, better survival rates for other cardiovascular diseases, and comorbidities such as hypertension, diabetes, and obesity.
 

Additionally, the burden of heart failure is increased by lifestyle factors and healthcare access disparities. For instance, in the U.S., adults over 65 years have a heart failure prevalence of 8.0%–9.1%, nearly four times higher than younger adults. In China, heart failure prevalence rose from 4.68 million in 1990 to 13.1 million in 2021, with an annual growth rate of 3.18%, outpacing global trends. These statistics underscore the urgent need for advanced therapeutic solutions like VADs, which offer life-saving support for patients with end-stage heart failure.
 

A ventricular assist device (VAD) is a mechanical pump that supports heart function and blood flow in individuals with weakened hearts. It helps circulate blood from the ventricles to the rest of the body, either temporarily or permanently, depending on the patient's condition.
 

Ventricular Assist Devices Market Trends

Technological advancements have significantly reshaped the market, enhancing device performance, safety, and patient outcomes.
 

• Innovations such as magnetic levitation (MagLev) technology, seen in Abbott’s HeartMate 3, have reduced mechanical wear and blood damage, improving long-term durability and reducing complications like thrombosis.
   
• Similarly, miniaturization of components has enabled more anatomically compatible devices, making implantation less invasive and expanding eligibility to a broader patient population.
   
• Moreover, the integration of wireless energy transfer, remote monitoring, and smart sensors is transforming VADs into connected therapeutic systems. These features allow clinicians to track device performance and patient vitals in real time, enabling proactive management and reducing hospital readmissions.
   
• Furthermore, biocompatible materials, adaptive flow algorithms, and fully implantable systems under development are pushing the boundaries of patient comfort and mobility.
   
• Thus, these advancements are not only improving clinical outcomes but also driving wider adoption across both developed and emerging healthcare markets.
   

Ventricular Assist Devices Market Analysis

Based on the product, the ventricular assist devices market is segmented into left ventricular assist devices (LVADs), right ventricular assist devices (RVADs), biventricular assist devices (BIVADs), and percutaneous ventricular assist devices. The left ventricular assist devices (LVADs) segment accounted for 48.2% of the market in 2024 due to its increasing adoption in patients with end-stage heart failure, rising prevalence of cardiovascular diseases, and advancements in device technology improving patient survival and quality of life. The segment is expected to exceed USD 2.6 billion by 2034, growing at a CAGR of 7.8% during the forecast period.
 

On the other hand, the percutaneous ventricular assist devices (pVADs) segment held a market share of 37.4% in 2024, and its growth can be attributed to the increasing adoption of minimally invasive procedures, which allow for rapid deployment in catheterization labs without the need for open-heart surgery.
 

• This dominance of LVADs is driven by the widespread use of these devices in treating end-stage heart failure, particularly in bridge-to-transplant and destination therapy applications. LVADs have become the preferred option due to their proven clinical outcomes, technological advancements like continuous-flow systems, and expanded reimbursement coverage in key markets.
   
• The right ventricular assist devices (RVADs) segment is expected to grow with a 9.4% CAGR during the analysis period. The segment is primarily driven by the increasing incidence of right-sided heart failure, advancements in miniaturized and biocompatible device designs, and the growing use of RVADs in bridge-to-transplant and recovery therapies, especially in complex cardiac cases requiring targeted ventricular support.
   
• The market for the biventricular assist devices (BIVADs) segment is expected to expand rapidly, driven primarily by the increasing number of patients with biventricular heart failure, advancements in dual-pump configurations, and the growing use of BiVADs as a bridge to transplant or recovery in complex cardiac cases where single-ventricle support is insufficient.
   

Based on application, the ventricular assist devices market is segmented into destination therapy, bridge-to-candidacy (BTC) therapy, bridge-to-transplant (BTT) therapy, bridge-to-recovery (BTR) therapy, and other applications. The destination therapy segment dominated the market in 2024 and is growing with a CAGR of 8.9% during the forecast period.
 

• This growth is primarily driven by the increasing adoption of long-term mechanical circulatory support for patients ineligible for heart transplants, improved device durability, and clinical evidence showing survival rates comparable to transplant outcomes, especially among younger cohorts.
   
• The second largest segment, bridge-to-transplant (BTT) therapy, held a market share of 25.9% in 2024. This segment continues to be supported by decades of clinical success, established surgical protocols, and favorable reimbursement frameworks, making it a cornerstone of mechanical circulatory support for patients awaiting heart transplantation.
   
• The bridge-to-candidacy (BTC) therapy segment is expected to grow with a 7.8% CAGR during the analysis period. This growth is primarily driven by the increasing number of patients who are initially ineligible for heart transplantation but may become eligible after stabilization with mechanical circulatory support, along with improved clinical outcomes and expanding use of VADs in complex heart failure management strategies.
   
• The market for the bridge-to-recovery (BTR) therapy segment is expected to expand rapidly, driven primarily by the increasing use of temporary mechanical circulatory support in post-cardiotomy and acute heart failure cases, where patients have a potential for myocardial recovery.
   
• On the other hand, the other applications segment held a market share of 5.6% in 2024, and its growth can be attributed to the increasing use of VADs in bridge-to-decision scenarios, post-cardiotomy support, and temporary circulatory stabilization, especially in patients with uncertain transplant eligibility or reversible cardiac conditions.
   

Based on the patient, the ventricular assist devices market is segmented into adults and pediatrics. The adults segment was anticipated to be worth USD 2.3 billion in 2024 and is expected to grow at an 8.2% CAGR during the forecast period.
 

• This growth is driven by the rising prevalence of advanced heart failure among aging populations, increasing adoption of destination therapy, and continuous technological advancements in device design and functionality.
   
• On the other hand, the market for the pediatrics segment is expected to grow at a 10.2% CAGR. This growth is primarily driven by the rising incidence of congenital heart defects, increasing demand for specialized pediatric cardiac care, and ongoing technological advancements in device miniaturization and biocompatibility tailored for younger patients.
   

Based on flow, the ventricular assist devices market is segmented into pulsatile flow and continuous flow. The continuous flow segment was anticipated to be worth USD 2.4 billion in 2024.
 

• Its dominance is further supported by widespread clinical adoption, lower complication rates, and strong long-term survival data across diverse patient populations. The segment is expected to maintain its lead due to ongoing innovations in pump design and energy efficiency.
   
• On the other hand, the market for the pulsatile flow segment is expected to grow at a 10.2% CAGR. Although less commonly used than continuous-flow devices, this segment is gaining traction due to its physiological mimicry of natural heartbeats, which can be beneficial in specific patient populations and recovery scenarios.
   

Based on design, the ventricular assist devices market is segmented into transcutaneous and implantable. The implantable segment was anticipated to be worth USD 2 billion in 2024.

• The strong preference for implantable VADs stems from their enhanced durability, improved patient outcomes, and technological advancements such as magnetic levitation pumps and wireless power systems. As the demand for long-term cardiac support continues to rise amid a growing heart failure population and limited donor availability, the implantable VAD segment is expected to remain a cornerstone of the market's growth trajectory.
   
• On the other hand, the market for the transcutaneous segment is expected to grow at a 8% CAGR. This growth is primarily driven by the increasing adoption of minimally invasive procedures, the expanding use of percutaneous micro-axial pumps, and the segment’s suitability for short-term cardiac support in high-risk PCI and cardiogenic shock cases.
   

Based on end use, the ventricular assist devices market is segmented into hospitals, cardiac catheterization labs, ambulatory surgical centers, and other end users. The hospitals segment dominated the market with a revenue share of 43.1% in 2024 and is expected to reach USD 2.4 billion within the forecast period.
 

• The growth in this segment is driven by the increasing number of advanced heart failure cases requiring surgical intervention and post-operative care in hospital settings.
   
• Hospitals continue to be the primary centers for VAD implantation, monitoring, and long-term management, making them critical to the market’s sustained growth.
   
• Moreover, the availability of skilled cardiac surgeons and advanced infrastructure in hospitals further reinforces their leading role in VAD adoption.
   
• The cardiac catheterization labs segment was valued at approximately USD 723.5 million in 2024, driven by the rising prevalence of cardiovascular diseases, increasing demand for minimally invasive procedures, and continuous advancements in imaging technologies such as intravascular ultrasound (IVUS) and optical coherence tomography (OCT).
   
• The market for the ambulatory surgical centers (ASCs) segment is expected to expand rapidly, driven primarily by the growing demand for minimally invasive and same-day procedures, favorable reimbursement policies, and the shift from inpatient to outpatient care models. ASCs offer cost-effective surgical solutions, reduced infection risks, and faster recovery times, making them increasingly attractive to both patients and healthcare providers.
   
• On the other hand, the other end users segment held a market share of 6.4% in 2024, and its growth can be attributed to the increasing adoption of VADs in specialty clinics and research institutions.
   

North America Ventricular Assist Devices Market

North America dominated the global market with the highest market share of 57.4% in 2024.
 

• The U.S. ventricular assist devices market was valued at USD 950.7 million and USD 1.1 billion in 2021 and 2022, respectively. The market size reached USD 1.3 billion in 2024, growing from USD 1.2 billion in 2023, and is anticipated to grow at a CAGR of 6.9% between 2025 to 2034.
   
• North America, particularly the U.S., has a high number of cases of congestive heart failure, with lifestyle-associated risk factors as the major causes. The CDC reported that in 2023, around 6.2 million people in the U.S. were patients of congestive heart failure, and 121.5 per 100,000 deaths were due to that condition.
   
• According to the American Heart Association, the percentage of obese people climbed to 41.9% in 2022, and diabetes was the ailment of 37.3 million Americans in 2021. The growing number of patients will be the main driver for the demand for advanced therapies, among which ventricular assist devices (VADs) are the most common, both as bridge-to-transplant and destination therapy.
   
• The U.S. Census Bureau predicts that people aged 65 and above will make up 17.5% of the total American population by 2024, implying that the incidence of heart failure and VAD use will increase. In 2023, there were 1,482 certified cardiac care centers all over the U.S. that have been playing a key role in the distribution of these devices and have been contributing to the expansion of the market.
   
• Moreover, the region boasts state-of-the-art cardiac care facilities, specialized hospitals, and well-established surgical centers capable of VAD implantation. This advanced infrastructure facilitates faster adoption of cutting-edge technologies and ensures proper postoperative monitoring. High standards of care and availability of trained healthcare professionals make VAD implantation more accessible and safer, driving demand.
   

Europe Ventricular Assist Devices Market

Europe market accounted for USD 821.4 million in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Several European governments provide substantial funding for advanced cardiac therapies and maintain an easy supply of medical devices through the national health systems. Programs that fund the implantation of VAD not only reduce the amount of money that patients have to pay out of their own pockets but also encourage hospitals to broaden their advanced heart failure treatment programs. These projects are spreading the technology of VAD more widely across the region.
   
• Further, there are very large heart transplant programs in the European region, especially in Germany, Spain, and the UK. Eurotransplant states that in 2022, Germany carried out 331 heart transplants, whereas Spain did 302 in the same period. Vented assist devices (VADs) are the means of transplant devices for patients who are waiting for a donor heart, as this leads to their increased use.
   
• According to UK NHS Blood and Transplant data, out of 179 heart transplant cases done in 2022-2023, about 40% of patients were on VADs as a bridge to transplantation. The development of transplant programs is the reason for the higher rate of VAD adoption because mechanical support is required both in short-term and long-term periods for these patients. The European Society of Cardiology stated that between 2021 and 2023, the number of VAD implantations at leading European transplant centers increased by 15%.
   

Asia Pacific Ventricular Assist Devices Market

The Asia Pacific market is anticipated to grow at the highest CAGR of 13.7% during the analysis timeframe.
 

• The economic growth in the region has made advanced cardiac treatments more affordable for the majority. Moreover, the Asia-Pacific region is turning into a medical tourism center, where patients from neighboring countries go to receive quality cardiac care. Thus, the demand for devices such as VAD is rising.
   
• Several governments in the region are implementing new policies to facilitate access to advanced cardiac therapies, giving as an example the reimbursement or insurance coverage for VAD implantation. Such programs cut down the financial burden on patients; thus, the market will grow at a faster pace.
   
• Additionally, hospitals in the region are increasingly adopting innovative medical technologies, including next-generation VADs with improved durability and minimally invasive designs. Acceptance of these advanced devices enhances patient outcomes and encourages further adoption by healthcare providers.
   

Latin America Ventricular Assist Devices Market

The Latin America market is experiencing robust growth over the analysis timeframe.
 

• In the Latin American region, the VADs market is significantly influenced by the occurrence of cardiovascular diseases that have escalated to advanced heart failure. The main reasons for this disease are urbanization, poor diets, and lifestyle changes. The shortage of donor hearts has led to an increased use of VADs as a bridge-to-transplant option in the area.
   
• The rising investments in the healthcare infrastructure, particularly in the specialized cardiac centers in the countries of Brazil, Mexico, and Argentina, have not only increased the availability of advanced cardiac therapies but also their adoption. Moreover, the demand is rising due to the increasing awareness about mechanical circulatory support among physicians and patients.
   
• Supportive government initiatives and emerging insurance coverage schemes are reducing treatment costs, making VADs more accessible. Finally, the gradual introduction of technologically advanced, durable, and minimally invasive devices is encouraging broader adoption across major Latin American markets.
   

Middle East and Africa Ventricular Assist Devices Market

The Middle East and Africa (MEA) market is experiencing notable growth over the analysis timeframe.
 

• The regional growth is being driven by the increase in cases of heart failure and other cardiovascular diseases as a result of the rising prevalence of diabetes, hypertension, and obesity. The inflow of capital into advanced healthcare infrastructures and the setting up of specialized cardiac centers in countries like the UAE, Saudi Arabia, and South Africa have facilitated the availability of VAD therapy.
   
• Subsidies and government schemes are making the devices affordable and encouraging their purchase. The rising number of healthcare professionals who accept mechanical circulatory devices as a viable treatment option is positively affecting the market.
   
• Moreover, medical tourism in the region is contributing to higher utilization of advanced cardiac devices. The gradual introduction of innovative, compact, and more durable VADs is further enhancing market growth.
   

Ventricular Assist Devices Market Share

Leading industry players such as Abbott, Berlin Heart, CorWave, Jarvik HEART, and Johnson & Johnson hold around 93% of the market share in the highly consolidated market. These companies maintain their leading position by combining strong product lines, business collaborations with healthcare providers, regulatory clearances, and consistent product innovation.
 

Abbott continues to lead the market with its flagship HeartMate 3 LVAD, which has demonstrated superior survival rates and reduced complications such as thrombosis and stroke. Abbott’s strength lies in its diverse cardiovascular portfolio, strategic acquisitions, and robust clinical data supporting its devices. The company’s focus on remote monitoring, AI-powered diagnostics, and minimally invasive technologies positions it as a dominant force in both developed and emerging markets.
 

Berlin Heart specializes in pediatric and paracorporeal VADs, with its EXCOR Pediatric device being the only FDA-approved VAD for infants and children. The company’s focus on clinical support, customized therapy programs, and collaborations with pediatric cardiac centers has made it a trusted name in specialized heart failure treatment. Berlin Heart’s strategic expansion into North America and Europe continues to strengthen its market share.
 

Meanwhile, other key players such as Johnson & Johnson, Berlin Heart and CorWave are reinforcing their market presence through specialized innovations and strategic expansion.
 

Ventricular Assist Devices Market Companies

A few of the prominent players operating in the ventricular assist devices industry include:

• Abbott
• Berlin Heart
• BrioHealth
• CorWave
• EVAHEART
• Jarvik HEART
• Johnson & Johnson

• Johnson & Johnson

Johnson & Johnson, through its Abiomed division, leads with the Impella heart pump platform, the world’s smallest heart pump device. The Impella CP, 5.5, and ECP models offer minimally invasive, temporary mechanical circulatory support, particularly for patients with cardiogenic shock and high-risk PCI.
 

• Abbott

Abbott distinguishes itself in the VAD market through its advanced blood flow technologies, which prioritize hemocompatibility, reduced complications, and long-term durability. The company’s devices are known for their fully magnetically levitated systems, which minimize wear and tear and improve patient outcomes. Abbott also integrates remote monitoring capabilities and digital health platforms to support clinicians in managing patients post-implantation. Its strong clinical trial data and global regulatory approvals reinforce its reputation for safety and efficacy across diverse patient populations.
 

• Berlin Heart

Berlin Heart is recognized globally for its specialization in pediatric and customized mechanical circulatory support solutions. Its systems are designed to accommodate a wide range of patient sizes and clinical needs, particularly in infants and children with end-stage heart failure. The company emphasizes pulsatile flow technology, which closely mimics natural heart function, and collaborates extensively with pediatric cardiac centers worldwide.
 

Ventricular Assist Devices Industry News:

• In March 2025, Cadrenal Therapeutics, Inc. signed a collaboration agreement with Abbott to support its pivotal TECH-LVAD trial, which aimed to evaluate the efficacy and safety of tecarfarin in patients with LVADs. Under the agreement, Abbott assisted Cadrenal in planning and executing the trial. This collaboration is expected to strengthen clinical research in anticoagulation for LVAD patients, potentially improving treatment outcomes and driving adoption of advanced VAD therapies in the market.
   
• In October 2022, Abiomed, a subsidiary of Johnson & Johnson, announced that the Impella RP Flex, a VAD with SmartAssist, received FDA pre-market approval (PMA) as safe and effective for treating acute right heart failure for up to 14 days. The device, implanted via the internal jugular vein, allows patient mobility and features dual-sensor technology to optimize management. This approval supports the adoption of innovative, patient-friendly VADs, enhancing market growth for right heart support devices.
   

The ventricular assist devices market research report includes an in-depth coverage of the industry with estimates and forecasts in terms of revenue in USD Million and volume in Units from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Left ventricular assist devices (LVADs)
• Right ventricular assist devices (RVADs)
• Biventricular assist devices (BIVADs)
• Percutaneous ventricular assist devices

Market, By Application

• Destination therapy
• Bridge-to-candidacy (BTC) therapy
• Bridge-to-transplant (BTT) therapy
• Bridge-to-recovery (BTR) therapy
• Other applications

Market, By Patient

• Adults
• Pediatrics

Market, By Flow

• Pulsatile flow
• Continuous flow
  • Axial continuous flow
  • Centrifugal continuous flow

Market, By Design

• Transcutaneous
• Implantable

Market, By End Use

• Hospitals
• Cardiac catheterization labs
• Ambulatory surgical centers
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE